In this article, Dr. Daniel Kota provides a mesenchymal stem cell review and explores the future of MSC therapy. Mesenchymal stem cells (MSCs) are multipotent cells that prefer to differentiate into cells of the musculoskeletal system, such as bone, cartilage, muscle and fat cells. However, MSCs can also be induced to become other cell types, as well as exert therapeutic effects by honing to sites of repair and secreting therapeutic agents.
I am honored to release this interview with Dr. Ramon Coronado, Executive Director at Lester Smith Medical Research Institute, who started working with exosomes while looking for mechanisms used by MSCs to exert their therapeutic effects. In this interview, we discuss the scientific importance of exosomes, therapeutic and diagnostic applications of exosomes, and their use within encapsulation/delivery systems.
Read on to learn how these extracellular vesicles could transform the future of modern medicine and explore their advantages and disadvantages as compared to cell therapeutics. [Read more…]
What is Cynata’s Cymerus™ Technology?
The Cymerus™ technology is a stem cell manufacturing platform being developed by Cynata Therapeutics Limited (ASX: CYP), an Australian regenerative medicine company. The Cymerus™ technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating mesenchymoangioblasts (MCAs), and subsequently, for differentiating the cells into mesenchymal stem cells (MSCs). [Read more…]
Founded by Dr. Jon Rowley, RoosterBio is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry. Its products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. I had the honor of interviewing Dr. Jon Rowley, who is now the CTO of RoosterBio.
In this interview, we explore RoosterBio’s recent product launches, collaborations, achievements during 2016, and future trajectory. [Read more…]
RoosterBio has announced the launch of the Regenerative Medicine (RM) industry’s first xeno-free (XF) hMSC cell banks to advance and simplify stem cell biomanufacturing. By incorporating XF starting materials at early stages, RM scientists can perform more clinically relevant work, resulting in an expedited path towards clinical testing programs. Due of the importance of this announcement, I followed up with Dr. Priya Baraniak, Director of BD & Strategic Marketing at RoosterBio, to further explore details of the launch. [Read more…]